ALXO

Over the past six months, ALX Oncology completed a registered offering, strengthening its balance sheet with net proceeds of $140.4 million. The company reported its first-quarter 2026 financial results, missing analysts' EPS expectations by $0.02, but the stock traded up by 11.2% during midday trading on May 8, 2026. Encouraging Phase 1b/2 data for evorpacept in combination with zanidatamab in heavily pretreated HER2-positive breast cancer patients was presented at ESMO Breast Cancer 2026. CEO Jason Lettmann sold 12,311 shares of the company's stock for $26,714.87. Analyst ratings have varied, including a downgrade, reaffirmed buy and sell ratings, and new coverage initiated. The stock's 52-week range has been between $0.40 and $2.66, closing at $2.08 as of May 8, 2026.